Arbutus Biopharm Stock Price, News & Analysis

Arbutus Biopharma (Nasdaq: ABUS) announced promising preliminary data from its ongoing Phase 1a/1b trial of the capsid inhibitor AB-836, aimed at treating chronic hepatitis B virus (cHBV) infection. The trial indicates that AB-836 is generally safe and well-tolerated, showing robust antiviral activity with a significant mean drop in HBV DNA levels. No serious adverse events were reported among healthy subjects or cHBV patients. The study continues, with 16 cHBV patients dosed in Part 3, and more data is expected to be presented in 2022.

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the appointment of Dr. Tram Tran to its Board of Directors. Dr. Tran is a prominent liver and viral disease expert with over 20 years of experience in academia and industry. Previously, she held key roles at Gilead Sciences and Cedars-Sinai Medical Center. Her expertise is expected to enhance Arbutus's efforts in developing a cure for chronic hepatitis B and treatments for coronaviruses. President and CEO William Collier expressed confidence that Dr. Tran's knowledge will be instrumental in advancing the company’s portfolio.

Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced promising long-term safety and efficacy data for its lead compound, AB-729, in treating chronic Hepatitis B. Results from a Phase 1a/1b clinical trial show sustained suppression of HBsAg levels up to 28 weeks post-treatment in patients, with no significant differences between 60 mg and 90 mg dosages. The treatment was well-tolerated, with no serious adverse events reported. Continued analysis of the treatment's impact on nucleos(t)ide analogue therapy is anticipated, as the company aims to transform HBV treatment.

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in the virtual fireside chat at the Jefferies London Healthcare Conference on November 18, 2021, at 8:00 am GMT / 3:00 am ET. Key executives, including CEO William Collier and Chief Scientific Officer Dr. Michael Sofia, will present during the event. A webcast will be available through Arbutus' website, with a replay accessible after the conference. The company focuses on developing treatments for chronic hepatitis B virus and coronaviruses, leveraging a diverse pipeline aimed at innovative solutions.

Arbutus Biopharma Corporation (Nasdaq: ABUS) reported its Q3 2021 financial results, highlighting key developments in its hepatitis B virus (HBV) treatment pipeline. The company has initiated a Phase 2a trial combining AB-729 with standard NA therapy and Peg-IFNα-2a, aiming for multiple data readouts in Q4 2021. Financially, Arbutus reported a net loss of $24.2 million, a slight increase from $21.8 million year-over-year. The company also extended its cash runway into Q2 2023, with $151.9 million in cash on hand as of September 30, 2021, amidst rising R&D expenses.

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the presentation of data on its GalNAc-siRNA, AB-729, at The Liver Meeting® 2021, occurring from November 12-15, 2021. The poster, titled "Low HBsAg levels maintained following cessation of the GalNAc-siRNA, AB-729," indicates that AB-729 is generally safe and demonstrates sustained HBsAg decline in chronic hepatitis B patients. Key findings show maintained HBsAg suppression in some patients for up to 20 weeks post-treatment.

Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its schedule for the Q3 2021 financial results and corporate update on November 4, 2021. The press release will be available at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. Investors can access the live webcast via the company's website. Arbutus is focused on developing treatments for chronic hepatitis B and coronaviruses, leveraging a diverse portfolio of assets.

Arbutus Biopharma Corporation (Nasdaq: ABUS) focuses on innovative therapies to combat chronic hepatitis B virus (HBV) infections and coronaviruses, including COVID-19. On September 28, 2021, the company announced participation in two key virtual investor conferences in October. The first is Chardan's 5th Annual Genetic Medicines Conference on October 4-5, featuring a fireside chat on October 5 at 4:30 PM ET. The second is the H.C. Wainwright HBV Virtual Conference on October 13, with a fireside chat at 1:00 PM ET. Webcast links are available on Arbutus' website, along with archived replays.

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the appointment of Lisa M. Caperelli as Vice President of Investor Relations, a newly created role. Caperelli, with 20 years of experience in investor relations within the biotech sector, will head strategy and communications reporting to CFO David Hastings. This change aims to enhance engagement with the investment community regarding Arbutus’ efforts in providing a functional cure for chronic hepatitis B and ongoing coronavirus therapies. Caperelli previously held roles at various biotech companies, including Harmony Biosciences.